SCHEMBL29434833

SCHEMBL29434833

Cc1ccc(Cl)c(S(=O)(=O)Nc2c(F)cc(C#Cc3ccccc3)cc2F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
ACLY P53396 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPY2R P49146 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GRM4 Q14833 1/20 0.39
PTGES2 Q9H7Z7 1/20 0.39
FBP1 P09467 2/20 0.38
MCL1 Q07820 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23010358 1.00 L3MBTL1 (0.43) L3MBTL1POLBHSD17B10THRBHPGD
SCHEMBL29434875 0.89 MCL1 (0.49) POLBHPGDALDH1A1ACLYMEN1
SCHEMBL23010370 0.89 MCL1 (0.49) POLBHPGDALDH1A1ACLYMEN1
SCHEMBL29666209 0.88 ALDH1A1 (0.49) POLBHPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL22980321 0.88 ALDH1A1 (0.49) POLBHPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL29434842 0.87 SLC22A12 (0.44) SMN1; SMN2ALDH1A1LMNAACLYMEN1
SCHEMBL22981705 0.87 SLC22A12 (0.44) SMN1; SMN2ALDH1A1LMNAACLYMEN1
SCHEMBL23010357 0.85 KMT2A (0.52) SMN1; SMN2ALDH1A1LMNAACLYMEN1
SCHEMBL29434802 0.85 KMT2A (0.52) SMN1; SMN2ALDH1A1LMNAACLYMEN1
SCHEMBL22981714 0.84 FFAR4 (0.39) THRBSMN1; SMN2LMNAACLYKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN claimed
US-12065399-B2 Arylsulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2024-08-20 US disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES ARSA, SULT1E1, STS L3MBTL1 1394/4885POLB 2748/4885HSD17B10 1053/4885
US-12065399-B2 Arylsulfonamide derivatives ARSA, SULT1E1, STS L3MBTL1 1394/4885POLB 2748/4885HSD17B10 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.